With over 80,000 new cases expected in 2026, kidney cancer remains a leading malignancy—yet outcomes are improving as treatment advances accelerate. This half-day symposium will spotlight the latest innovations in managing localized and metastatic disease, equipping clinicians with practical, evidence-based strategies to enhance patient care.